Publications

Heterogeneity of Residual Disease After Neoadjuvant Systemic Therapy in Breast Cancer

 126
Heterogeneity of Residual Disease After Neoadjuvant Systemic Therapy in Breast Cancer

Tags:

Previous Article

Defining microglial-synapse interactions

Next Article

Clinical sequelae of gut microbiome development and disruption in hospitalized p...

Related Posts

ACLY inhibition promotes tumour immunity and suppresses liver cancer

ACLY inhibition promotes tumour immunity and suppresses...

 120

A humanized NOVA1 splicing factor alters mouse vocal communications

A humanized NOVA1 splicing factor alters mouse vocal co...

 91

Fasting primes small intestinal regeneration after damage via a microbiome–metabolite–chromatin axis

Fasting primes small intestinal regeneration after dama...

 41